The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes |
| |
| Authors: | Vu?H.?Duong mailto:vduong@umm.edu" title=" vduong@umm.edu" itemprop=" email" data-track=" click" data-track-action=" Email author" data-track-label=" " >Email author,Eric?Padron,Najla?H.?Al?Ali,Jeffrey?E.?Lancet,Jeff?Hall,Brian?Kwok,Ling?Zhang,Pearlie?K.?Epling-Burnette,Alan?F.?List,Rami?S.?Komrokji |
| |
| Affiliation: | 1.University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center,Baltimore,USA;2.Department of Malignant Hematology,H Lee Moffitt Cancer Center & Research Institute,Tampa,USA;3.Genoptix Medical Laboratory,Carlsbad,USA;4.Hematopathology and Laboratory Medicine,H Lee Moffitt Cancer Center & Research Institute,Tampa,USA;5.Immunology Program,H. Lee Moffitt Cancer Center & Research Institute,Tampa,USA |
| |
| Abstract: | ![]()
The prognostic value of peripheral blasts (PB) is not well-studied in patients with myelodysplastic syndromes (MDS). We evaluated the impact of PB on overall survival (OS) and transformation to acute myeloid leukemia (AML) in a large cohort. The MDS database at the Moffitt Cancer Center was retrospectively reviewed to identify patients with ≥?1% PB (PB-MDS) and those without PB (BM-MDS). We also assessed the correlation between PB and gene mutations. One thousand seven hundred fifty-eight patients were identified, among whom 13% had PB near the time of diagnosis. PB-MDS patients were more likely to be younger with trilineage cytopenia, complex karyotype, higher-risk disease, transfusion dependence, and therapy-related MDS. The rate of AML transformation was 49 vs. 26% (p?p?n?=?4) was 100% compared to 81% in the BM-MDS group (n?=?47). The presence of PB in MDS is an adverse independent prognostic variable that refines prognostic discrimination. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
